Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $48 from $45 and keeps an Equal Weight rating on the shares. Redemplo’s approval in FCS last week “importantly sets the stage for meaningful label expansion into SHTG,” the analyst tells investors. Phase 3 SHASTA 3 & 4 studies of plozasiran in SHTG are on track for Q3 of 2026 and management pointed to “a decent chance for success on pancreatitis,” the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Promising Growth with Redemplo Launch and Strategic Developments in Obesity Treatments
- Arrowhead Pharmaceuticals: Hold Rating Amid Redemplo Launch and Financial Stability
- Arrowhead Pharmaceuticals Reports Transformative Year-End Results
- Arrowhead reports FY25 EPS (1c), consensus (3c)
- Arrowhead options imply 11.3% move in share price post-earnings